New Meaning for Extended Release
Pfizer had hoped to secure FDA approval last fall, but the agency gave conditional approval in September for Lyrica as an epilepsy treatment. At the same time, it also gave conditional clearance of the drug for treating pain associated with shingles and nerve pain associated with diabetes.
The agency also rejected Pfizer's petition that Lyrica be used as a treatment for generalized anxiety disorder. Hamm said Pfizer intends to continue pursuing FDA approval of the drug for this indication.
In December, the FDA approved the drug for the two pain indications. Monday's ruling by the FDA enables Pfizer to conduct marketing campaigns identifying the drug as approved for seizure. Doctors are permitted by law to prescribe a drug for any disease as long as the FDA approves the drug for a single disease or condition, but companies can't market the drug for unapproved uses.
Pfizer's stock was up 20 cents to $27.88 Monday afternoon.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV